Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31329960 | 0.92 | GRIN2D (0.33) | IDO1EGLN2 | |
| SCHEMBL11261587 | 0.79 | CSNK1E (0.31) | FLT3CSNK1E | |
| SCHEMBL2484426 | 0.79 | TLR7 (0.33) | FLT3IDO1 | |
| SCHEMBL8240750 | 0.76 | FLT3 (0.35) | FLT3IDO1 | |
| SCHEMBL14668767 | 0.76 | CSNK1E (0.30) | CSNK1E | |
| SCHEMBL25080099 | 0.76 | GRIN2D (0.33) | CSNK1E | |
| SCHEMBL5401158 | 0.76 | TLR7 (0.49) | — | |
| SCHEMBL8240168 | 0.76 | CSNK1E (0.33) | FLT3CSNK1E | |
| SCHEMBL274851 | 0.75 | AXL (0.34) | IDO1 | |
| SCHEMBL12272663 | 0.73 | GABRA1 (0.48) | FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4593836-A2 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | Board of Regents, The University of Texas System (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250243209-A1 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-07-31 | — | — | US | disclosed |
| US-12365685-B2 | Substituted fused aromatic ring derivative, composition and use thereof | SHENZHEN TARGETRX, INC. (CN) | 2025-07-22 | — | — | US | disclosed |
| CN-117777136-B | 1, 3-Disubstituted tetrahydropyrrole derivative and preparation method and application thereof | 沈阳药科大学 | 2025-04-29 | — | — | CN | disclosed |
| CN-119894513-A | Heterocycles as modulators of NSD activity | 德州大学系统董事会 | 2025-04-25 | — | — | CN | disclosed |
| EP-3904355-B1 | SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF | SHENZHEN TARGETRX INC (CN) | 2024-11-20 | — | — | EP | disclosed |
| US-20240262830-A1 | IRE1A MODULATORS AND USES THEREOF | NIMBUS IASO, INC. | 2024-08-08 | — | — | US | disclosed |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | PHARMARON UK LTD. (GB) | 2024-05-09 | — | — | US | disclosed |
| WO-2007058942-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058873-A2 | IMIDAZOPYRAZINES AS CYCLIN DEPENTEND KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| WO-2007056468-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| US-20060014744-A1 | Midazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic | MERCK SHARP & DOHME LTD. (GB) | 2006-01-19 | — | — | US | disclosed |
| WO-2004041826-A1 | IMIDAZOPYRAZINONES AND IMIDAZOTRIAZINONES DERIVATES AS GABA-A RECEPTOR ANXIOLYTIC | MERCK SHARP & DOHME LIMITED (GB) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | FLT3 516/4885IDO1 15/4885EGLN2 2318/4885 |
| US-20240262830-A1 | IRE1A MODULATORS AND USES THEREOF | XBP1, HSPA5, ERN2 | FLT3 4127/4885IDO1 4741/4885EGLN2 1190/4885 |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | EIF2AK4, GCN1, CLN6 | FLT3 4768/4885IDO1 4654/4885EGLN2 559/4885 |
| US-20060014744-A1 | Midazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic | GABRA3, GABRA2, GABRA1 | FLT3 1141/4885IDO1 1853/4885EGLN2 2272/4885 |
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | FLT3 2386/4885IDO1 1978/4885EGLN2 1730/4885 |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | FLT3 650/4885IDO1 1186/4885EGLN2 1883/4885 |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | CHEK1, CHEK2, CDKN1A | FLT3 337/4885IDO1 819/4885EGLN2 4026/4885 |
| US-12365685-B2 | Substituted fused aromatic ring derivative, composition and use thereof | BRAF, ALK, TYRO3 | FLT3 6/4885IDO1 2040/4885EGLN2 2550/4885 |
| US-20250243209-A1 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | NSD3, NCOA1, NR1D1 | FLT3 2571/4885IDO1 3466/4885EGLN2 3924/4885 |
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | FLT3 344/4885IDO1 1046/4885EGLN2 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.